IMU-838 (30 mg/day)

Drug identity checked against registry records

Also recorded as Vidofludimus Calcium, Oral Tablet (30 mg/day)

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS)NCT03846219Immunic AGPhase 2Active not recruiting2020-04-24Actual

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.